Approved indications (U.S.): Febuxostat is approved for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable; it is not recommended for asymptomatic hyperuricemia.

Off-label uses: Clinicians may sometimes use febuxostat off label for difficult-to-control hyperuricemia in settings such as chronic kidney disease or tumor lysis–related uric acid elevation when other options are unsuitable, based mainly on small clinical studies and observational experience rather than large outcome trials.

Efficacy expectations:

• Serum uric acid levels usually begin to fall within a few days, and many patients reach a target below 6 mg/dL within 2 to 4 weeks, especially on the 80 mg dose.
• Over months of sustained urate lowering, gout flares generally become less frequent and less severe, and tophi (urate lumps) may shrink or disappear, although this can take many months to years.
• Compared with standard allopurinol doses, febuxostat more often achieves target uric acid levels, but it has not clearly improved overall clinical outcomes and carries a higher observed risk of cardiovascular death, so it is generally reserved for patients who cannot use allopurinol.

Typical dosing: For chronic management of hyperuricemia in adults with gout, the usual starting dose is 40 mg taken by mouth once daily; if serum uric acid remains above 6 mg/dL after about two weeks, the dose may be increased to 80 mg once daily, while patients with severe kidney impairment are generally limited to 40 mg once daily.

How to take: Swallow the tablet once a day at the same time each day, with or without food or antacids, and continue taking it every day even when you feel well; your clinician may prescribe colchicine or a nonsteroidal anti-inflammatory drug (NSAID) during the first several months to reduce gout flares triggered by changing uric acid levels.

Special dosing instructions: Do not start febuxostat in the middle of a severe gout flare unless directed, but if a flare occurs after you are already taking it, you are usually advised to continue the drug and treat the flare separately; your provider will periodically check blood tests such as serum uric acid and liver function to guide dosing.

Missed dose: If you miss a dose, take it as soon as you remember on the same day, but skip it if it is almost time for your next scheduled dose, and never take two doses at once to make up for a missed dose.

Overdose: If you or someone else takes more than the prescribed amount or a child swallows the medicine, contact a poison control center immediately (in the U.S., 1-800-222-1222) or seek emergency medical care.

Common side effects: The most frequent side effects include gout flares soon after starting therapy, nausea, joint pain, mild rash, and increases in liver enzymes; these are usually mild to moderate and tend to occur in the first weeks to months of treatment.

• Gout flares are common when uric acid levels first begin to fall and often decrease over time as urate stores are depleted.
• Mild digestive upset, headache, or fatigue may occur and often improve as the body adjusts.
• Laboratory tests may show elevated liver enzymes without symptoms, which is why periodic blood tests are recommended.

Serious or rare adverse effects (seek urgent care):

• Heart-related events such as chest pain, sudden shortness of breath, feeling faint, fast or irregular heartbeat, or symptoms of stroke (sudden weakness, trouble speaking, severe headache), especially in patients with prior cardiovascular disease.
• Severe allergic or skin reactions, including widespread rash, blistering or peeling skin, mouth or eye sores, facial or tongue swelling, or trouble breathing.
• Signs of serious liver problems such as dark urine, yellowing of the skin or eyes, severe fatigue, or right upper abdominal pain.

Warnings and precautions: Febuxostat carries a boxed warning in the U.S. for an increased risk of cardiovascular death compared with allopurinol, so it should be used mainly when allopurinol is not effective or not tolerated, particularly in people with existing heart disease or stroke history.

It should be used cautiously in patients with significant liver disease, with baseline and periodic liver function tests; dose reduction is needed in severe kidney impairment, and its safety and effectiveness have not been established in children.

Data in pregnancy and breastfeeding are limited, so other options are usually preferred and febuxostat is used only if clearly needed after weighing risks and benefits.

Overall safety compared with other gout drugs: Febuxostat is effective at lowering uric acid but, because of its cardiovascular risk signal, is typically considered a second-line urate-lowering therapy after allopurinol, while offering an option for patients who cannot tolerate allopurinol or uricosuric agents.

Side-effect reporting and safety updates: Patients and health professionals can report suspected side effects to the FDA’s MedWatch program by phone or online and should check FDA drug safety communications or the product Medication Guide for the latest warnings and precautions about febuxostat.

Major drug interactions: Febuxostat strongly inhibits xanthine oxidase and is contraindicated with azathioprine or mercaptopurine because it can greatly increase their levels and cause severe bone marrow toxicity; it also alters the metabolism of theophylline, so caution and monitoring are advised if these medicines are used together.

Other medicines and substances: Clinically important interactions with most common blood-pressure drugs, statins, or pain relievers are not expected, but diuretics, high-dose aspirin, and other drugs that raise uric acid may counteract its effect; always tell your clinician about all prescription and over-the-counter medicines, vitamins, and herbal supplements you use.

Food, alcohol, and lifestyle: There are no specific food restrictions with febuxostat, but limiting alcohol (especially beer and spirits), sugar-sweetened drinks, and very high-purine foods can improve gout control and reduce the need for higher doses.

Precautions and who should be careful: Extra caution is needed in people with prior heart attack, stroke, or other serious cardiovascular disease because of the increased risk of cardiovascular death seen with febuxostat, and in those with significant liver or kidney disease or a history of severe skin reactions to urate-lowering drugs.

Monitoring needs: Regular blood tests are usually recommended, including serum uric acid to ensure the target level is reached and maintained, liver function tests to watch for liver injury, and kidney function in patients with renal impairment, along with clinical monitoring for chest pain, neurologic symptoms, or unusual rashes.

Q: How long does it take for febuxostat to start working on my gout?
A: Uric acid levels usually begin to fall within a few days of starting febuxostat, but it often takes several months of steady treatment before gout attacks become less frequent and tophi, if present, begin to shrink.

Q: Will my gout flares get worse when I first start febuxostat?
A: It is common to have more or stronger gout flares during the first few months as urate crystals mobilize, which is why doctors often prescribe colchicine or an NSAID at the same time; over time, flares typically become less frequent as uric acid is controlled.

Q: Is febuxostat better than allopurinol?
A: Febuxostat often lowers uric acid to target levels more reliably than standard allopurinol doses, but because it has been linked to a higher risk of cardiovascular death, guidelines usually recommend trying allopurinol first and using febuxostat mainly when allopurinol is not effective or not tolerated.

Q: Can I take febuxostat if I have kidney problems?
A: Febuxostat can be used in many patients with kidney disease, but those with severe kidney impairment are generally kept on a lower maximum dose (40 mg once daily), and kidney function will be monitored regularly.

Q: Should I stop febuxostat if I have a gout attack?
A: In most cases you should keep taking febuxostat during a gout flare and use other medicines, such as colchicine or NSAIDs, to treat the pain, because stopping and starting urate-lowering therapy can make gout harder to control.

Storage: Store febuxostat tablets at room temperature (about 68°F to 77°F / 20°C to 25°C) in the original, tightly closed container, protected from moisture, heat, and light, and keep them out of reach of children and pets.

Do not store the medicine in the bathroom or other very humid places, and do not use tablets that are chipped, discolored, or past the expiration date.

Disposal: Whenever possible, take unused or expired tablets to a pharmacy or community medicine take-back program; if none is available, mix tablets (uncrushed) with an undesirable substance such as used coffee grounds or kitty litter, seal in a bag or container, and place in the household trash, and do not flush them down the toilet unless specifically instructed.